The primary objectives of associated medical research are the identification and clinical application of specific medications for SARS-CoV-2 in order to remedy this condition. According to genetic test results, there is a 79.5% sequence identity between SARS-CoV-2 and the SARS-CoV that erupted in Beijing 17 years ago, despite the fact that the two viruses are substantially different. Additional sequence alignment revealed that there was a 96.1% similarity in the main protease sequences between SARS-CoV-2 and SARS-CoV. This significant protease plays a crucial role in the virus's life cycle and is a valuable target for therapeutic discovery. Effectively binding protease inhibitors are anticipated to be a key tool in the fight against disease progression.
For more: https://sars-cov-2.creative-biolabs.com/protease-inhibitors-for-the-treatment-of-sars-cov2.htm